• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Faron Pharmaceuticals

0.47 EUR-0.11 %19/8 16:16
5,758 following

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Dividend
Investor consensus
Compare
-0.11 %
-4.79 %
-4.01 %
-6.58 %
-76.60 %
-80.49 %
-85.68 %
-90.97 %
-86.01 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
106.42M EUR
Turnover
95.02K EUR
P/E (adj.) (26e)
-4.52
EV/EBIT (adj.) (26e)
-5.2
P/B (26e)
81.04
EV/S (26e)
24,704.74
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
2026-03-11
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-03-12

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
BEXAR is also recruiting: euclinicaltrials.eu Clinical Trials in the European Union - EMA A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA (BEXAR Study) See also the link: clinicaltrials.gov ClinicalTrials...
8/13/2026, 2:26 PM
by Kulkuri
36
While waiting for better times to read: There has been talk about this on the forum before, but now the research by Maija & co. has been published (Aug 10) for closer scientific scrutiny. The publication explains why physical exercise alone is not enough to “cure” cancer: However...
19 hours ago
by Kulkuri
23
Fairly recent talk on e.g., Kontro / BEX + AUDIO only (NO video) Timestamps as follows: 00:00:57 – Whole genome insights (Alex Bataller) 00:02:31 – Luspatercept and disease modification (Pinkal Desai) 00:05:42 – EPO-PRETAR trial and ESA-IPSS-M score benefits (Sophie Park) 00:10:39...
8/17/2026, 1:45 PM
by Kulkuri
21
The share price reaction tells us a lot about the precarious situation we are dangling in. The main thing, however, is that Maija and her team are doing fantastic, consistent work and science is progressing, so we can believe in the future. Hopefully, the finance side finds good ...
8/12/2026, 3:18 PM
by Raikku
18
Exactly, the fact that it is possible to expand the trials on a large scale. You would think that Big Pharma companies would be itching to get their hands on this. A year is a short time, but on the other hand, it’s a long time to wait. Faron cannot afford to wait until the finish...
8/12/2026, 4:23 PM
by Raikku
16
That point from Maija (the “dummy food” [tuttiruu]) and the associated observation (the “code whiz” [koodinikkari]) open up so many new avenues for research that the deep pockets of BP would really start to be necessary.
8/13/2026, 4:24 AM
by Kulkuri
9
so it would be possible that the next steps might involve preclinical studies of: bex + venetoclax and bex + cytostatics used in AML treatment?
8/12/2026, 4:13 PM
by Koodinikkari
5
Read more on our forum
Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/8
2026

Interim report Q2'26

Regulatory press release2026-08-19 08:00

Faron Pharmaceuticals Ltd: Notice of Half-Year Financial Results

Faron Pharmaceuticals
Regulatory press release2026-08-05 13:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-08-04 15:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-08-03 14:00

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

Faron Pharmaceuticals
Faron reports first OS results from frontline MDS patients
Analyst Comment2026-07-28 08:33 by
Antti Siltanen

Faron reports first OS results from frontline MDS patients

Median overall survival has not been reached in 2/3 of patient groups after 14.9 months of follow-up.

Faron Pharmaceuticals
Regulatory press release2026-07-27 08:00

Inside Information: Faron announces encouraging first overall survival data from frontline higher-risk (HR) MDS patients in the BEXMAB phase 1/2 trial

Faron Pharmaceuticals
Regulatory press release2026-07-24 08:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Faron updated the status of investigator-initiated bexmarilimab studies
Analyst Comment2026-07-14 08:16 by
Atte Riikola

Faron updated the status of investigator-initiated bexmarilimab studies

The bexmarilimab cohort in the FINPROVE trial was discontinued, but the company's own blood cancer trials are moving forward.

Faron Pharmaceuticals
Press release2026-07-13 08:00

Faron Provides Update on Investigator-Initiated Trial Portfolio for Bexmarilimab

Faron Pharmaceuticals
Regulatory press release2026-07-01 12:00

Faron Pharmaceuticals Ltd: Grant of Options

Faron Pharmaceuticals
Regulatory press release2026-06-22 15:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-17 15:30

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-17 08:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Press release2026-06-16 14:58

Redeye: Faron Pharmaceuticals: Matured BEXMAB data from EHA and BEXERA update

Faron Pharmaceuticals
Faron's BEXMAB update provided additional information on response duration
Analyst Comment2026-06-16 08:15 by
Antti Siltanen

Faron's BEXMAB update provided additional information on response duration

According to the company, the Phase 2b BEXERA trial will start in H2'26.

Faron Pharmaceuticals
Regulatory press release2026-06-15 17:00

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Faron Pharmaceuticals EHA 2026
Webcast2026-06-15 15:00

Faron Pharmaceuticals EHA 2026

Faron Pharmaceuticals
Press release2026-06-15 08:00

Faron Presents Matured BEXMAB Data at EHA 2026 Confirming Durable Efficacy and Bone Marrow Reprogramming in HR-MDS

Faron Pharmaceuticals
Regulatory press release2026-06-11 16:05

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals
Regulatory press release2026-06-11 16:00

Faron Pharmaceuticals Ltd: Registration of Treasury Shares

Faron Pharmaceuticals